Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This phase I/Ib trial studies the side effects and best dose of talazoparib given together
with gemtuzumab ozogamicin and to see how well they work in treating patients with CD33
positive acute myeloid leukemia that has come back (relapsed) or does not respond to
treatment (refractory). Talazoparib may stop the growth of cancer cells by blocking some of
the enzymes needed for cell growth. Gemtuzumab ozogamicin is a protein (antibody) combined
with a chemotherapy drug which specifically targets acute myeloid leukemia cells expressing a
marker (CD33). Adding talazoparib to the gemtuzumab ozogamicin therapy may lead to an
increased effectiveness in treatment.